PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer
Latest Information Update: 13 Dec 2022
At a glance
- Drugs Avelumab (Primary)
- Indications Adenocarcinoma; Neuroendocrine carcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms PICK-NEPC
- 13 Feb 2021 Results presented at the 2021 Genitourinary Cancers Symposium
- 12 Feb 2021 Status changed from active, no longer recruiting to completed.
- 06 Apr 2020 Planned End Date changed from 31 Dec 2022 to 9 Jan 2023.